ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 14時41分
Source:
Eisai
エーザイ、2020年3月期配当予想の修正(増配)に関するお知らせ
東京, 2019年07月31日 - (JCN Newswire) - 当社は、2019年7月31日開催の取締役会において、2020年3月期第2四半期末(中間)配当の予想について、下記の通り、修正(増配)することを決議しましたので、お知らせします。
1. 配当予想の修正について
2020年3月期第2四半期末(中間)配当の予想の修正(増配)
年間配当金(円)
第2四半期末/期末/合計
前回予想(2019年5月13日公表)70円00銭/80円00銭/150円00銭
今回修正予想 80円00銭/80円00銭/160円00銭
当期実績 -/-/-
前期実績(2019年3月期)70円00銭/80円00銭/150円00銭
2. 修正の内容
当社は、主要なステークホルダーズである患者様と生活者の皆様、株主の皆様および社員の価値増大をはかるとともに良好な関係の発展・維持に努めています。
配当につきましては、長期的なバランスシートマネジメントに依拠した「最適資本構成に基づく最適配当政策」を志向しており、連結業績、DOE(親会社所有者帰属持分配当率)およびフリー・キャッシュ・フローを総合的に勘案し、「シグナリング効果」も考慮して、株主の皆様へ継続的・安定的な配当を実施します。配当のKPIとしては、連結純資産に対する配当の比率を示すDOEを採択しています。
今回、これらの配当方針、ならびに好調な業績に基づく強固なバランスシートを勘案し、前回発表(2019年5月13日)の2020年3月期第2四半期末(中間)配当金予想を10円増配の80円に修正します。2010年3月期以来となる増配により期末配当金予想80円と合わせ、年間配当金予想は160円(前回予想は150円)、2020年3月期通期業績予想に基づくDOEは7.1%となる見込みです。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201959.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 04:50 JST
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2025 13:29 JST
NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups
Feb 19, 2025 20:16 JST
Mitsubishi Power Advances Bahrain's Industrial Growth with Completion of Alba's Power Station 5 Block 4 Combined Cycle Power Plant Project
Feb 19, 2025 16:54 JST
Honda Reveals Specification for its Next-generation Fuel Cell Module
Feb 19, 2025 11:07 JST
NEC Orchestrating Future Fund invests in Aetion, a U.S.-based provider of healthcare analytics platforms
Feb 19, 2025 09:08 JST
Osaka Gas and MHI Launch CO2NNEX Digital Platform for Management and Transfer of Clean Gas Certificates for e-Methane, for Use during Expo 2025
Feb 18, 2025 13:18 JST
TOYOTA GAZOO Racing starts WEC season with Qatar challenge
Feb 17, 2025 18:45 JST
FLAT OUT IN TOKYO "Red Bull Showrun x Powered by Honda" April 2 (Wed)
Feb 17, 2025 16:21 JST
Thrilling TOYOTA GAZOO Racing one-two on Swedish snow
Feb 17, 2025 14:23 JST
Launch of Joint Demonstration Experiment of Remote Provision of GPU Computing Power
Feb 17, 2025 14:10 JST
Mazda to Strengthen Production and Sales Systems in Thailand
Feb 14, 2025 17:04 JST
Toyota Develops New Fuel Cell System
Feb 14, 2025 15:27 JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 14, 2025 12:09 JST
Nissan, Honda and Mitsubishi Motors terminate MOU regarding consideration of tripartite collaboration
Feb 13, 2025 16:20 JST
More Latest Release >>
Related Release
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
1/22/2025 5:18:00 PM JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/15/2025 10:03:00 AM JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
More Press release >>